|
Recent Developments |
|
14-FEB-13
Wockhardt, one of the leading pharmaceutical and biotechnology companies, reported a surge of 2.01 times in consolidated net profit for third quarter to Rs 4.27 billion as compared to Rs 2.12 billion in the same period last year.
08-JAN-13
Wockhardt, one of the leading pharmaceutical and biotechnology companies, has received final approval from the United States Food ans Drug Administration (US FDA) for marketing 25mg, 50mg, 100mg, 2... More.. |
| Business Profile |
Future Plans |
|
| CEO Talk | | Wockhardt Ltd is exploring possibilities of co-licensing WCK-771 and WCK-919. The company intends to focus essentially on the anti-infective therapeutic segment as it accounts for 12 per cent of the total pharma market and is the third largest therapeutic segment. Habil Khorakiwala |
|
|
One To One
|
|
Recent news
|
|
|
| Period ending (months) | 31-Dec-2012(9) | 31-Mar-2012 (12) | 31-Mar-2011 (12) | | Net sales | 17670.50 | 25604.00 | 17549.20 | | Other Income | 129.80 | 201.20 | 170.90 | | Total Income | 17800.30 | 25805.20 | 17720.10 | | Cost of goods sold | 14084.30 | 17265.30 | 13465.40 | | OPBDIT | 3716.00 | 8539.90 | 4254.70 | | PAT | 4662.80 | 1840.00 | -1320.70 | | Gross Block | - | - | - | | Equity capital | 547.80 | 547.20 | 547.20 | | EPS (Rs.) | - | 16.81 | -12.07 | | DPS (Rs.) | - | - | - | | BV (Rs.) | - | - | - | | P/E range (x) | - | 14.95 - 36.99 | NA | | Debt / Equity (x) | - | - | - | | Operating margin (% of OI) | 20.9 | 33.1 | 24.0 | | Net margin (% of OI) | 26.2 | 7.1 | -7.5 |
|
|
Detailed Financials
|
|
|
|
|
Snapshot
